Trending News
- Enhanced Recovery after Surgery (Eras) and Immunonutrition: An Evidence-based Approach
- Redhill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to over 40 Million Additional Americans
- Fujifilm Earns Fda “breakthrough Device” Designation for Endosurgical Image Enhancement Technology
- Cognitive Deficit and White Matter Changes in Celiac Disease
- Family History of Colorectal Cancer and Prevalence of Advanced Colorectal Neoplasia in Screening
- Enhanced Recovery after Surgery (Eras) and Immunonutrition: An Evidence-based Approach
- Redhill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to over 40 Million Additional Americans
- Fujifilm Earns Fda “breakthrough Device” Designation for Endosurgical Image Enhancement Technology
- Cognitive Deficit and White Matter Changes in Celiac Disease
- Family History of Colorectal Cancer and Prevalence of Advanced Colorectal Neoplasia in Screening
- Enhanced Recovery after Surgery (Eras) and Immunonutrition: An Evidence-based Approach
- Redhill Biopharma Extends Talicia® Unrestricted National and Regional Commercial Coverage to over 40 Million Additional Americans
- Fujifilm Earns Fda “breakthrough Device” Designation for Endosurgical Image Enhancement Technology
- Cognitive Deficit and White Matter Changes in Celiac Disease
- Family History of Colorectal Cancer and Prevalence of Advanced Colorectal Neoplasia in Screening
- This event has passed.
17th World Congress on Insulin Resistance, Diabetes, and Cardiovascular Disease (WCIRDC)
December 5, 2019 - December 7, 2019
The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 17th year, is a unique and exciting multidisciplinary program. The Congress is the premiere global meeting dedicated to diabetes, obesity, lipids, cardiovascular disease (CVD), and energy balance, linking basic research to clinical practice, and highlighting the theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.
Approved for AMA PRA Category 1 Credits™